☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
biocon
Biocon’s Yesafili (Biosimilar, Eylea) Receives the US FDA’s Approval for Ophthalmology
May 21, 2024
Biocon Enters into an Exclusive License Agreement with Bayer and Regeneron for the Commercialization of Yesafili (biosimilar, afli...
March 4, 2024
Biocon Biologics Enters into a Exclusive License Agreement with Sandoz for the Commercialization of Ogivri (biosimilar, trastuzuma...
February 9, 2024
PharmaShots Weekly Snapshots (October 09–13, 2023) _
October 14, 2023
Biocon Entered into a Commercialization Agreement with Juno Pharmaceuticals for Liraglutide to Treat Type 2 diabetes and Obesity i...
October 10, 2023
Biocon Reports P-I Study (RHINE-3) Results of Biosimilar Insulin
December 25, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.